Giovanna Bossi, PhD, is Principal Scientist at Immunocore Ltd. She has over 16 years’ experience in research and development in industry, gained at Immunocore Ltd, UK. Giovanna leads cell biology research and preclinical activities aiming to develop TCR-based therapeutics for treatment of autoimmune diseases such as T1 diabetes and vitiligo. Giovanna joined the Disease Biology Autoimmune group in 2017 after spending previous 9 years in Research Oncology where she contributed to understand mechanism of action of the first in human ImmTAC (tabentafusp, or Kimmtrack commercial name) for treatment of uveal melanoma and cutaneous melanoma. KIMMTRAK® is the first and only FDA-approved treatment that, in a randomized clinical trial, was proven to significantly extend overall survival for HLA-A*02:01–positive adults with uveal melanoma that cannot be removed by surgery or has spread.
Following the completion of her DPhil from the Cellular Immunology Unit at the University of Pavia (Italy), Post Doctoral Research associated positions at Cancer Institute IFOM-IEO in Milan and at the Sir William Dunn School of Pathology at University of Oxford, she joined Immunocore Ltd in 2006. Her area expertise span from T cell biology to cancer immunotherapy and autoimmune immunotherapy on which she has presented at international meetings and has contributed to various publications.